What was the process for the introduction of the HBV NAT?
We actively monitor emerging technologies and the donor screening approaches used across the industry. We have previously undertaken a cost/benefit evaluation regarding the implementation of HBV NAT, which recommended that routine implementation of hepatitis B NAT would be of benefit provided the testing was able to be undertaken on single donations given the estimated prevalence in Australia. This has now been made possible with the recent availability of fully automated NAT testing platforms. We have since participated in an international study evaluating the two commercially available automated NAT platforms which both provide HBV NAT. A business case and formal tender process was completed and, in line with government funding approval, the implementation planning to introduce this technology is now well advanced. We are working closely with the Therapeutic Goods Administration (TGA) to ensure that the testing is introduced at the earliest opportunity. It is anticipated that testing
